Skip to main content

estradiol and progesterone (Bijuve®)

 

Status: Medicine does not meet criteria for AWMSG assessment

Excluded from appraisal by AWMSG as meets exclusion criteria 5. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information.

Medicine details

Medicine name estradiol and progesterone (Bijuve®)
Formulation 1mg/ 100mg soft capsules
Reference number 4496
Indication

Continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses

Company Theramex
BNF chapter Endocrine system
Assessment type N/A
Status Medicine does not meet criteria for AWMSG assessment
Date of issue 20/10/2022
Follow AWTTC: